selexipag: Clinical Trials

9 trials of selexipag, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 9 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	9	Completed 6, Active not recruiting 1, Recruiting 1, Terminated 1

Follow selexipag: new trials by email Literature Review of selexipag trials Research Report on selexipag

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option Macitentan, Selexipag, Macitentan/Tadalafil FDC - Hypertension, Pulmonary	Phase 3	Recruiting	Actelion	280	2022-05-04	2026-11-03
A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study Selexipag - Hypertension, Pulmonary	Phase 3	Completed	Actelion	43	2021-05-03	2025-05-01
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist - Hypertension, Pulmonary	Phase 3	Active not recruiting	Actelion	138	2020-01-16	2026-11-03
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment Selexipag, Placebo - Chronic Thromboembolic Pulmonary Hypertension	Phase 3	Terminated	Actelion	128	2019-01-23	2024-06-21
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension i.v. selexipag, oral selexipag (Uptravi) - Pulmonary Arterial Hypertension	Phase 3	Completed	Actelion	20	2017-12-04	2025-06-29
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension Macitentan, Tadalafil, Selexipag - Pulmonary Arterial Hypertension	Phase 3	Completed	Actelion	247	2016-05-01	2025-03-30
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension Selexipag - Pulmonary Arterial Hypertension	Phase 3	Completed	Actelion	34	2015-10-12	2018-01-23
ACT-293987 in Pulmonary Arterial Hypertension ACT-293987 - Pulmonary Arterial Hypertension	Phase 3	Completed	Actelion	709	2010-07-07	2025-03-30
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Selexipag, Placebo - Pulmonary Arterial Hypertension	Phase 3	Completed	Actelion	1156	2009-12-01	2025-10-27

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding